Filed Sep 23, 2026 · sources re-read Sep 24, 2026

Finasteride vs minoxidil: not the same kind of decision

One is a prescription tablet acting on a hormone pathway; the other is an over-the-counter topical that does not. Comparing them on effectiveness alone misses the point.

Written from documents. Checked by no clinician.

Everything on this page comes out of published paperwork — drug labels, regulator bulletins, assessment reports — read by someone who is not a doctor and cannot examine you. It is not medical advice, and there is no medical reviewer standing behind it. Plenty of hair loss has a cause that needs diagnosing rather than treating, so put any decision to start something, change something or stop something to a GP or a dermatologist first.

You will find no doses on this site. What strength, for whom, and whether at all, is a decision for a prescriber holding your history — not for a web page.
The MHRA’s own advice to patients on the tablet licensed for hair loss is to stop it and contact a doctor as soon as possible if depression or suicidal thoughts develop, and to speak to a doctor about any change in sexual function. That is the regulator’s instruction, published 11 May 2026.
If you have harmed yourself or feel at risk of serious harm, call your local emergency number now — 999 in the UK, 911 in the US, 112 across the EU.

Searched as a head-to-head, this question almost always gets answered as one — a winner, a runner-up, a recommendation. The documents do not support that framing, and not because the evidence is thin. It is because the two are different categories of thing: one needs a prescriber and acts on a hormone pathway, the other is bought off a shelf in much of the world and does not.

The comparison that actually matters

Two medicines, side by side on the things that differ
	Finasteride	Minoxidil (topical)
What it acts on	Blocks the enzyme converting testosterone to DHT, lowering DHT in blood and scalp	Not the DHT pathway; originally a blood-pressure medicine, used on the scalp
How you get it	Prescription only	Over the counter in the US and many other countries
Who it is licensed for	Men only, in its hair-loss licence; contraindicated in pregnancy	Products exist for men and for women; read the specific carton
The safety question people ask	Sexual and psychiatric effects, and reports of persistence after stopping	Mostly local — irritation — plus warnings on the carton about wider effects
Regulator attention recently	Four safety documents between 2024 and 2026 across three agencies	Long-established over-the-counter labelling
What stopping does	Label: withdrawal reverses the effect within twelve months	Benefit is likewise not retained after stopping, per the carton

Look down the first column of that table rather than across the rows. The difference in kind is bigger than any difference in degree. One of these decisions involves a clinician assessing whether a systemic hormone-pathway drug is appropriate for you; the other involves reading a carton.

Why we are not giving you an effectiveness winner

Because no regulator has published one. The FDA label for finasteride reports its own trials against placebo, not against minoxidil. Minoxidil's labelling does the same. Head-to-head trials exist in the literature, in varying sizes and qualities, and quoting a single one as though it settled the matter is precisely how this subject fills with confident, undated claims.

What can be said without inventing anything: finasteride's licensed evidence base is unusually well described, with five-year blinded photograph ratings and hair counts published in the label itself. Those figures are laid out here. Minoxidil's case rests on its own trials and its own labelling.

What each is licensed to claim

A licence is a promise a regulator has agreed to let a company make, and the two promises here are not the same shape.

Finasteride's hair-loss licence is narrow and heavily qualified. Men only. The US label adds that efficacy in bitemporal recession — the corners at the temples — has not been established, and the supporting trials enrolled men aged 18 to 41 with mild to moderate loss. It is a licence to treat a particular pattern in a particular population, not a licence to treat baldness.

Topical minoxidil's claims live on an over-the-counter carton, which is a different genre of document: written to be read by a purchaser with no clinician present, with its warnings in the imperative and its directions on the box. Comparing the two documents directly is comparing a prescribing information dossier with a package you can pick up in a shop.

The hidden cost of being over the counter

Availability without a prescription is usually presented as an unqualified advantage. It has one cost that matters in this subject specifically: nobody is obliged to work out what is wrong with you first.

Hair loss is a symptom with many causes. Thyroid disease, iron deficiency, alopecia areata, scarring alopecias, telogen effluvium after illness or stress, and reactions to other medicines all present as thinning hair, and none of them is pattern hair loss. A prescription route forces at least one conversation with someone who could notice that. Buying a carton does not, and months can pass.

That is the argument for seeing a doctor whichever product you are drawn to — and it is the one piece of advice on this site that costs nothing and earns nothing.

The asymmetry in the safety conversation

This is where an honest comparison earns its keep. Finasteride's safety record has been reviewed, argued over and acted on by three major regulators in the space of two years, and the documents describe effects that some people report as persisting after the drug is stopped. Nothing of that shape sits in the topical minoxidil record.

That asymmetry has two possible readings and only one of them is safe to assert. The unsafe reading is that finasteride is dangerous and minoxidil is not. The supportable reading is narrower: a systemic prescription medicine acting on a hormone pathway attracts a different kind of scrutiny than a topical acting locally, and the documents reflect that. What the finasteride record does say, precisely, is set out on the side-effect page.

Which question are you actually asking?

In practice the choice is rarely a pure comparison, because the two options have different entry costs.

If you have not seen a doctor about the hair loss, neither answer is the next step. Thyroid disease, iron deficiency, alopecia areata, scarring alopecias and telogen effluvium all look like thinning and none of them is treated by either of these.
If you want to start with something you can stop easily and buy yourself, that is an argument about access and reversibility, not about which molecule is stronger.
If you are considering the prescription route, the questions worth taking to the appointment are on the finasteride page — including the things a prescriber is supposed to ask you first.
If you are considering both at once, the attribution problem is real and under-discussed: using them together.

Two different failure modes

When each of these disappoints someone, it tends to disappoint them in a characteristic way, and knowing the shape in advance is more useful than a verdict.

Finasteride disappoints slowly and invisibly. Its strongest effect is preventing loss, and prevented loss is not something you can see. Men stop because nothing seems to be happening, which is also what success looks like from the inside.
A topical disappoints through friction. It has to be applied, it sits in hair, it can irritate, and it competes with getting out of the house. Adherence is the usual reason a topical fails, not pharmacology.
Both disappoint when the diagnosis was wrong. Neither treats the conditions listed above, and neither will tell you that it is not working for that reason.

Only the first of those three is a question about the molecule.

The honest summary

Finasteride has the more thoroughly published efficacy data and the more contested safety record. Topical minoxidil has the lower barrier to trying and the quieter file. Neither is a cure, both stop working when stopped, and the only comparison that settles anything is the one a clinician makes with your diagnosis in front of them.

Choosing between them

Can I use both?

People do, and they act by unrelated mechanisms, which is the rationale. What combining costs you is the ability to attribute any change — good or bad — to one of them, which is worth raising with a prescriber before starting both at once.

Which one has fewer side effects?

They have different ones, and the records are not comparable in quality. The finasteride figures come from placebo-controlled trials and decades of reporting reviewed by three regulators; comparing those directly with over-the-counter labelling would be comparing two different kinds of document.

Does starting one rule out the other later?

Nothing in the documents suggests it does. They act by unrelated mechanisms and neither label describes the other as a contraindication. What starting both at once does cost you is the ability to tell which one produced any change you notice.

Is one cheaper?

Both are long off patent and sold generically, so in most markets the medicines themselves are not where the cost sits. What differs is that one requires a consultation and the other does not — and prices vary too much by country and pharmacy for this site to quote a figure it has not verified.

The whole medicine, in one place: what finasteride is and what it does — or the record of what the side-effect documents actually say. Information only, written from published sources, not reviewed by a clinician.